$USNA

USANA (USNA) held its Q2 2026 earnings call. Management said Core Nutritional was stable, with Mainland China showing renewed strength. The company recorded a preliminary $29 million noncash goodwill impairment and $9 million income tax expense on a $19 million pretax loss. USANA ended the quarter with $169 million cash, zero debt, and $20 million free cash flow, and lowered its fiscal 2026 outlook due to HYA DTC marketing and Rise net sales.

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.

USANA Health Sciences (NYSE:USNA) reported Q2 CY2026 sales of $223 million, down 5.4% year on year, missing market expectations and sending the stock down 19.2% to $18.41. The company said full-year revenue guidance is $962.5 million at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was a $0.07 loss, better than consensus.

USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsreleaseex991.htm EX-99.1 Document USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (N

USANA Health Sciences (NYSE:USNA) is set to report Q2 earnings Tuesday after the bell. Last quarter, it reported $250.2M revenue, flat YoY, and beat analysts on EBITDA and EPS. For Q2, analysts expect flat YoY revenue, after a 10.8% rise last year. The article cites an average analyst price target of $39 versus $22.11.

USANA Health Sciences (NYSE: USNA) reported results from a 12-week consumer study of its Glow skincare supplement. The trial involved 36 participants in the US and Mexico. About 97.2% reported brighter-looking, more even-toned, and more radiant skin; 86.1% reported improved hydration, and 83.3% reported improved firmness and elasticity.

Jones Paul A. (CHIEF PEOPLE OFFICER) sold 5,561 shares of USANA HEALTH SCIENCES INC (USNA) at $18.50 ($0.10M total) on 2026-06-08.

Fleming John Turman sold 2,450 shares of USANA HEALTH SCIENCES INC (USNA) at $17.93 on 2026-06-01.

Jones Paul A. (CHIEF PEOPLE OFFICER) sold 6,813 shares of USANA HEALTH SCIENCES INC (USNA) at $18.95 ($0.13M total) on 2026-05-28.